With its strong industry knowledge, deep local understanding and extensive network of partners, DKSH will support Merdury in its market penetration. Once imported, the products will be distributed by local distribution partners.
DKSH partners with Merdury to bring new solution to treat diabetes
Founded in July 2019, Merdury focuses on developing solutions to meet the needs of medical treatment. With the exclusive StackDose™ platform created based on 3D powder printing process and technology, along with unique drug binding formula, Merdury develops new tablet dosage forms with controlled dissolution time and precise absorption at the exact site. Products manufactured by Merdury also help improve the bioavailability of active pharmaceutical ingredients (APIs) to optimize the product's effect, thereby limiting the dosage and minimizing side effects.
Mr. Edward Lin, Chairman of Merdury Biopharmaceutical Corporation shared at the signing ceremony: "Vietnam is one of our key markets as we aim to expand our business outside Taiwan with advanced diabetes treatments. With DKSH's expertise and extensive network of partners, Merdury will achieve its development goals in the Vietnamese market in the future."
Mr. Phillip Wray, General Director, DKSH Pharma Vietnam, said: "This MOU marks an important first step in our journey to bring fast-acting treatment for type 2 diabetes to the Vietnamese market. Furthermore, we are pleased to become a trusted partner of Merdury to jointly improve access to multiple treatments for diabetes patients."
Source
Comment (0)